1Brown ML, Houn F, Sickels EA, et al. Screening mammography in community practice: positive predictive value of abnormal findings and yield of follow-up diagnostic procedures[J]. A JR, 1995,16:1373-1377.
2Scheidhauer K, Walter C, Seemann M. FDG PET and other imaging modalities in the primary diagnosis of suspicious breast lesions[J]. Eur J Nucl Med Imaging, 2004, 31 :S70-S79.
3Kumar R, Alavi A. Fluorodeoxyglucose-PET in the management of breast cancer[J]. Radiol Clin North Am, 2004, 42(6): 1113-1122.
4Minn H, Soini I. [18F]Fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer [J].Eur J Nucl Med, 1989, 15:61-66.
5Dehdashti F, Mortimer JE, Siegel F, et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays [J]. J Nucl Med,1995, 36:1766-1774.
6Bombardieri E, Crippa F, Maffoli L, et al. Axillary lymph node metastases detection with nuclear medicine approaches in patients with newly diagnosed breast cancer: can positron emission tomography with FDG be considerd as the best method[J]. Int J Oncol, 1996, 8:693-699.
7Avril N, Dose J, Janicke F, et al. Metabolic characteristics of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose[J]. J Clin Oncol, 1996, 14:1848-1857.
8Scheidauer K, Scharl S, Pietrzyk U, et al. Qualitative F-18 FDG positron emission tomography in primary breast cancer: clinical relevance and practicability[J]. Eur J Nucl Med, 1996, 23:618-623.
9Noh DY, Yun IJ, Kim JS, et al. Diagnostic value of positron emission tomography for detecting breast cancer [J]. World J Surg,1998, 22:223-228.
10Hubner KF, Smith GT, Thie JA, et al. The potential of F18-FDG PET in breast cancer: detection of primary lesions, axillary lymph node metastases, or distant metastases [J]. Clin Pos Imag,2000, 3:197-205.
